Howard Fein, MD
MOHS-Micrographic Surgery · Rolling Hills Estates, CANPI 1184707838
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,023 of the $18,894 with a category attached, or 68.9%. Incyte Corporation accounts for 73.5% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2022 at $7,327 and has fallen 83.0% since, to $1,243 in 2025. Among mohs-micrographic surgery clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $72.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$14K
- Sanofi$973
- AbbVie$770
- Regeneron Healthcare Solutions, Inc.$433
- Pfizer$372
- Mimedx Group, Inc.$350
- plus $2K from 22 others
Across 1 payment — averaging $512.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$512
What the payments were for
- Speaking & faculty fees$13,02369%
- Grants$600%
- Travel & lodging$4963%
- Food & beverage$5,30028%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 21 | $13,883 |
| Sanofi | 37 | $973 |
| AbbVie(2 entities) | 40 | $770 |
| Regeneron Healthcare Solutions, Inc. | 16 | $433 |
| Pfizer | 26 | $372 |
| Mimedx Group, Inc. | 8 | $350 |
| UCB, Inc. | 24 | $337 |
| Novartis | 11 | $266 |
| Johnson & Johnson | 11 | $258 |
| Sun Pharmaceutical Industries Inc. | 10 | $199 |
| Arcutis Biotherapeutics, Inc. | 8 | $173 |
| Galderma Laboratories, L.p. | 9 | $142 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $124 |
| Mayne Pharma Commercial LLC | 6 | $120 |
| Amgen | 4 | $86 |
| Almirall LLC | 4 | $79 |
| LEO Pharma Inc. | 3 | $78 |
| Dermira, Inc. | 2 | $39 |
| Verrica Pharmaceuticals Inc. | 1 | $33 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Organon | 2 | $21 |
| Journey Medical Corporation | 1 | $20 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| Sebela Pharmaceuticals Inc. | 1 | $18 |
| Strata Skin Sciences, Inc. | 1 | $18 |
| Bsn Medical Inc | 1 | $15 |
| Sandoz | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$13,773
How this compares
$18,894 in reported general payments places this provider in the 90th percentile of 144 mohs-micrographic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 12 | $73,973 |
| Dupixent PenDupilumab | 15 | $56,311 |
| Fluocinonide | 159 | $6,351 |
| Fluorouracil | 57 | $3,695 |
| Ketoconazole | 143 | $2,735 |
| Clindamycin Phosphate | 39 | $2,390 |
| Metronidazole | 29 | $1,426 |
| Ciclopirox | 38 | $1,371 |
| Ammonium Lactate | 64 | $1,271 |
| Desonide | 18 | $1,076 |
| Imiquimod | 19 | $896 |
| Mupirocin | 105 | $866 |
| Clobetasol Propionate | 12 | $707 |
| CiclopiroxCiclopirox Olamine | 30 | $657 |
| ValacyclovirValacyclovir Hcl | 32 | $643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $770 | $73,97312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 mohs-micrographic surgery providers in California.
Other mohs-micrographic surgery in Rolling Hills Estates
- Sarah ArronBurlingame$98K
- Daniel Zelacla Jolla$43K
- Ralph MasseySanta Monica$38K
- Michael MortazieOrange$29K
- Sumaira AasiStanford$27K
- Andrea WilleySacramento$21K
- Benjamin Kelleyla Jolla$20K
- Frank NoodlemanSaratoga$19K
- Joanna ChanLong Beach$18K
- Jared LundFresno$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.